Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-09-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于不向下修正健帆转债转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 健帆生物科技集团股份有限公司 regarding the decision not to downward adjust the conversion price of its convertible bonds (健帆转债). It details the bond issuance, listing, historical adjustments to the conversion price, the conditions under which the conversion price can be adjusted downward, and the board's resolution not to adjust the price at this time. The document is a formal disclosure about a capital/financing matter related to convertible bonds and their conversion price adjustments. It is not a full financial report, earnings release, or management discussion, but rather a specific update on financing terms and corporate actions related to capital structure. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4624 characters, which is sufficient for a detailed announcement rather than a brief notice. No indication that this is a report publication announcement or regulatory filing only. Hence, the classification is CAP with high confidence.
2025-09-12 Chinese
第五届董事会第三十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 32nd meeting of the 5th Board of Directors of the company. It details the meeting attendance, the agenda discussed, and the voting results on a specific proposal related to convertible bond conversion price adjustment. There is no financial data, no full report, no earnings or audit information, and no presentation. The document is clearly a Board/Management Information announcement about board decisions and related governance matters. It is not a full report or a regulatory filing of another type. Therefore, the appropriate classification is 'MANG' for Board/Management Information.
2025-09-12 Chinese
关于预计触发转股价格向下修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company about the expected triggering of a downward adjustment condition for the conversion price of its convertible bonds. It includes extensive historical data on bond issuance, conversion price adjustments, and the conditions under which the conversion price may be adjusted downward. The document is an official announcement related to convertible bond terms and price adjustments, not a financial report, earnings release, or management discussion. It is regulatory in nature, providing investors with important information about bond conversion price adjustments and related corporate actions. It does not contain financial statements or detailed financial analysis, nor is it a report of voting results or a proxy solicitation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2025-09-05 Chinese
2025年半年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (465 characters) indicating that the company has approved its 2025 half-year report and that the full report and summary will be published on a specified website the next day. It does not contain the actual financial data or the full report itself, but rather informs investors about the upcoming publication of the half-year report. According to the 'MENU VS MEAL' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2025-08-21 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "健帆生物科技集团股份有限公司 2025 年半年度报告全文" which translates to "Jafron Biomedical Co., Ltd. 2025 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business description, product information, and regulatory compliance details. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of financial metrics, management analysis, and detailed business operations confirms this is a semi-annual financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-08-21 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 31st meeting of the 5th Board of Directors of the company. It includes approval of the 2025 semi-annual report and related financial matters, but the actual semi-annual report is referenced as being published elsewhere (on the official disclosure website). The document is short (1274 characters) and primarily serves to announce the board meeting decisions and approvals, not to present the full financial report itself. Therefore, it is a Board/Management Information announcement rather than the Interim/Quarterly Report itself.
2025-08-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.